Get started
Author

Frank Luh

Observed institution: Chinese Anti-Cancer Association
ORCID: 0000-0001-6841-9586
Observed ORCID: 0000-0001-6841-9586
OpenAlex ID: A5126542787
Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al. · Cancer Research Communications · 2
PDF
Nanobody-engineered CLL-1 CAR T cells: A strategy for safer targeting in acute myeloid leukemia
2026 · Chakrapani Tripathi, Frank Luh, et al. · Molecular Therapy Oncology
Abstract 5190: Advancing FCRL5 directed immunotherapy for improved treatment of B cell lymphoma
2026 · Chakrapani Tripathi, John Nguyen, et al. · Cancer Research
Supplementary Figure S6 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Supplementary Figure S1 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Supplementary Figure S3 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Supplementary Figure S5 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Supplementary Figure S7 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Figure 2 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Figure 1 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Data from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Figure 6 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Figure 3 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Graphical Abstract from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Figure 4 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Figure 5 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Supplementary Figure S8 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Supplementary Figure S4 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Supplementary Figure S2 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Figure 7 from Nanobody-Engineered CLL-1 CAR T Cells: Optimizing Tumor-Specific Cytotoxicity and Minimizing Off-Tumor Toxicity
2026 · Chakrapani Tripathi, Sergey Zolov, et al.
Works count: 20
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type